Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07452406 · ClinicalTrials.gov registry record · NA
Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
A NA study, sponsored by Rush University Medical Center.
- Not yet
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
NCT07452406 is a NA study that has not yet begun recruiting, run by Rush University Medical Center. The registered enrollment target is 2,000 participants.
The verdict
NCT07452406, a NA study, has not yet begun recruiting, sponsored by Rush University Medical Center.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
Study Summary
High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In many hospitals, these decisions vary from clinician to clinician. This study will compare usual care with a standardized step-by-step plan for reducing HFNC support. Eight hospitals will participate and will switch from usual care to the standardized plan at different time points during the study. The main goal is to determine whether the standardized weaning plan increases the number of patients who can successfully stop HFNC within 5 days. The study will also evaluate how long patients remain on HFNC, whether they need additional breathing support, and how long they stay in the hospital. The results may help develop clearer guidance for safely and efficiently stopping HFNC therapy.
Interventions
- BEHAVIORAL Protocolized HFNC Weaning Strategy
- BEHAVIORAL Usual Care HFNC Weaning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-06-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07452406
The ClinicalTrials.gov registry entry for NCT07452406 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Protocolized HFNC Weaning Strategy is the first listed.
NCT07452406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07452406 about?
NCT07452406 is a clinical study titled "Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients". High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In ...
What is the current status of trial NCT07452406?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2026-09-01. Estimated completion is 2028-06-28.
What interventions are being tested in trial NCT07452406?
The interventions under investigation include: Protocolized HFNC Weaning Strategy (BEHAVIORAL), Usual Care HFNC Weaning (BEHAVIORAL).
Who is sponsoring clinical trial NCT07452406?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.